<?xml version='1.0' encoding='utf-8'?>
<document id="29255511"><sentence text="Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation."><entity charOffset="45-55" id="DDI-PubMed.29255511.s1.e0" text="dabigatran" /></sentence><sentence text="Dabigatran is a direct thrombin inhibitor used to decrease the risk of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF)"><entity charOffset="0-10" id="DDI-PubMed.29255511.s2.e0" text="Dabigatran" /></sentence><sentence text=" Its prodrug, dabigatran etexilate (DE) is often co-administrated with a proton pump inhibitor (PPI) because of its adverse effects on the gastrointestinal tract"><entity charOffset="14-34" id="DDI-PubMed.29255511.s3.e0" text="dabigatran etexilate" /><entity charOffset="36-38" id="DDI-PubMed.29255511.s3.e1" text="DE" /><pair ddi="false" e1="DDI-PubMed.29255511.s3.e0" e2="DDI-PubMed.29255511.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29255511.s3.e0" e2="DDI-PubMed.29255511.s3.e1" /></sentence><sentence text=" Drug-drug interactions between DE and PPIs in daily clinical practice have not been fully elucidated"><entity charOffset="32-33" id="DDI-PubMed.29255511.s4.e0" text="DE" /></sentence><sentence text="" /><sentence text="Changes in blood dabigatran concentration (DC) were investigated using the dilute thrombin time test in a randomized, open-label, two-period crossover study including 34 Japanese patients with NVAF receiving dabigatran therapy with or without PPI"><entity charOffset="17-27" id="DDI-PubMed.29255511.s6.e0" text="dabigatran" /><entity charOffset="208-218" id="DDI-PubMed.29255511.s6.e1" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.29255511.s6.e0" e2="DDI-PubMed.29255511.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29255511.s6.e0" e2="DDI-PubMed.29255511.s6.e1" /></sentence><sentence text="" /><sentence text="The average trough DC was significantly higher without PPI than with PPI (83 ± 42" /><sentence text="3 vs" /><sentence text=" 55" /><sentence text="5 ± 24" /><sentence text="6 ng/mL, respectively; P &lt; 0" /><sentence text="001)" /><sentence text=" Similarly, the average peak DC was significantly higher without PPI than with PPI (184" /><sentence text="1 ± 107" /><sentence text="7 vs" /><sentence text=" 124 ± 59" /><sentence text="2 ng/mL, respectively; P = 0" /><sentence text="0029)" /><sentence text=" The average ratio of DC change at the trough and peak levels did not differ significantly among the three PPI types" /><sentence text="" /><sentence text="PPI administration significantly decreased the trough and peak DCs in patients with NVAF" /><sentence text=" Therefore, when prescribing PPIs for patients with NVAF in a clinical setting, the possibility that the bioavailability of dabigatran may decrease should be considered"><entity charOffset="52-56" id="DDI-PubMed.29255511.s23.e0" text="NVAF" /><entity charOffset="124-134" id="DDI-PubMed.29255511.s23.e1" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.29255511.s23.e0" e2="DDI-PubMed.29255511.s23.e0" /><pair ddi="false" e1="DDI-PubMed.29255511.s23.e0" e2="DDI-PubMed.29255511.s23.e1" /></sentence><sentence text="" /></document>